[go: up one dir, main page]

AR105991A1 - Heteroarilos sustituidos con pirazolilo y su uso como medicamentos - Google Patents

Heteroarilos sustituidos con pirazolilo y su uso como medicamentos

Info

Publication number
AR105991A1
AR105991A1 ARP160102777A ARP160102777A AR105991A1 AR 105991 A1 AR105991 A1 AR 105991A1 AR P160102777 A ARP160102777 A AR P160102777A AR P160102777 A ARP160102777 A AR P160102777A AR 105991 A1 AR105991 A1 AR 105991A1
Authority
AR
Argentina
Prior art keywords
group
independently
alkyl
haloalkyl
heteroatoms
Prior art date
Application number
ARP160102777A
Other languages
English (en)
Inventor
Mcarthy Clive
Scott John
Fandrick Daniel
Gnamm Christian
Dahmann Georg
Hoffmann Matthias
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR105991A1 publication Critical patent/AR105991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Compuesto caracterizado por la fórmula (1), en donde A es N o CH; en donde Y es -O- o CH₂; en donde R³ es un sustituyente en posición orto o en posición meta del anillo pirazolilo de la fórmula (1) y se selecciona del grupo que consiste en -alquilo C₁₋₆ lineal o ramificado, -haloalquilo C₁₋₆, -cicloalquilo C₃₋₆, -alquilen C₁₋₄-cicloalquilo C₃₋₆, un heterociclo monocíclico de cinco o seis miembros con 1, 2 o tres heteroátomos seleccionados cada uno, de modo independiente, O, S o N, un heterociclo bicíclico de 9 a 10 miembros con 1, 2 ó 3 heteroátomos seleccionados cada uno, de modo independiente, O, S o N, en donde R³ está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes cada uno seleccionado, de modo independiente entre si, del grupo que consiste en halógeno (F), -alquilo C₁₋₃, oxo, -CN; en donde R² se selecciona del grupo que consiste en -alquilo C₁₋₃, -haloalquilo C₁₋₃, F, Bʳ, Cₗ; ʸ ₗₐₛ ₛₐₗₑₛ ᶠₐʳₘₐᶜéᵘₜⁱᶜₐₘₑₙₜₑ ₐᶜₑₚₜₐᵇₗₑₛ ᵈₑ ₗₒₛ ᶜₒₘₚᵘₑₛₜₒₛ ₐₙₜₑₛ ₘₑₙᶜⁱₒₙₐᵈₒₛ.
ARP160102777A 2015-09-11 2016-09-09 Heteroarilos sustituidos con pirazolilo y su uso como medicamentos AR105991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562217269P 2015-09-11 2015-09-11

Publications (1)

Publication Number Publication Date
AR105991A1 true AR105991A1 (es) 2017-11-29

Family

ID=56852283

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102777A AR105991A1 (es) 2015-09-11 2016-09-09 Heteroarilos sustituidos con pirazolilo y su uso como medicamentos

Country Status (19)

Country Link
US (2) US9845314B2 (es)
EP (1) EP3347353B1 (es)
JP (1) JP6868011B2 (es)
KR (1) KR20180051624A (es)
CN (1) CN108026080B (es)
AR (1) AR105991A1 (es)
AU (1) AU2016320297B2 (es)
CA (1) CA2998250A1 (es)
CL (1) CL2018000400A1 (es)
DK (1) DK3347353T3 (es)
EA (1) EA033978B1 (es)
ES (1) ES2745284T3 (es)
HU (1) HUE046920T2 (es)
IL (1) IL257392B (es)
MX (1) MX2018003008A (es)
PH (1) PH12018500533A1 (es)
PL (1) PL3347353T3 (es)
TW (1) TW201720799A (es)
WO (1) WO2017042100A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN106029653A (zh) 2014-01-31 2016-10-12 达纳-法伯癌症研究所股份有限公司 二氨基嘧啶苯砜衍生物及其用途
JP6535022B2 (ja) * 2014-03-19 2019-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロアリールｓｙｋ阻害剤
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩並三唑並二氮雜環庚三烯及其用途
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
US9845314B2 (en) 2015-09-11 2017-12-19 Boehrnger Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments
RU2742035C2 (ru) 2015-11-25 2021-02-01 Дана-Фарбер Кэнсер Инститьют, Инк. Бивалентные ингибиторы бромодоменов и пути их применения
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
EP1799673A1 (en) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
JP5055263B2 (ja) * 2005-03-30 2012-10-24 ダエウン ファーマシューティカル カンパニー リミテッド 抗真菌性トリアゾール誘導体
CA2732087A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as medicaments
CA2731926A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
PE20120121A1 (es) * 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
CN102822172A (zh) 2010-01-29 2012-12-12 贝林格尔.英格海姆国际有限公司 取代的二氮杂萘及其作为syk 激酶抑制剂的用途
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US8921383B2 (en) 2011-03-28 2014-12-30 Hoffmann-La Roche Inc. Thiazolopyrimidine compounds
MX336224B (es) 2011-07-26 2016-01-12 Boehringer Ingelheim Int Quinolinas sustituidas y su uso como medicamentos.
US9145414B2 (en) * 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
BR112014030410A2 (pt) 2012-06-07 2017-06-27 Hoffmann La Roche inibidores de pirazolopirimidona e pirazolopiridona de tanquirase
AP2015008532A0 (en) 2012-12-18 2015-06-30 Hulow Llc Syk kinase inhibitors as treatment for malaria
KR101750667B1 (ko) * 2013-07-31 2017-07-04 길리애드 사이언시즈, 인코포레이티드 Syk 억제제
JP2017505337A (ja) * 2014-01-10 2017-02-16 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としてのインダゾール化合物
JP6535022B2 (ja) 2014-03-19 2019-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロアリールｓｙｋ阻害剤
TW201617074A (zh) * 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
US9845314B2 (en) 2015-09-11 2017-12-19 Boehrnger Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments

Also Published As

Publication number Publication date
JP6868011B2 (ja) 2021-05-12
PL3347353T3 (pl) 2020-01-31
PH12018500533A1 (en) 2018-09-10
EA033978B1 (ru) 2019-12-16
DK3347353T3 (da) 2019-10-21
JP2018529679A (ja) 2018-10-11
MX2018003008A (es) 2018-04-11
HUE046920T2 (hu) 2020-03-30
ES2745284T3 (es) 2020-02-28
US20170073333A1 (en) 2017-03-16
CL2018000400A1 (es) 2018-07-13
CN108026080A (zh) 2018-05-11
KR20180051624A (ko) 2018-05-16
TW201720799A (zh) 2017-06-16
AU2016320297B2 (en) 2020-08-27
EP3347353B1 (en) 2019-07-17
US10155751B2 (en) 2018-12-18
EA201890695A1 (ru) 2018-09-28
EP3347353A1 (en) 2018-07-18
CA2998250A1 (en) 2017-03-16
AU2016320297A1 (en) 2018-02-08
WO2017042100A1 (en) 2017-03-16
CN108026080B (zh) 2021-06-11
US20180148433A1 (en) 2018-05-31
US9845314B2 (en) 2017-12-19
IL257392B (en) 2020-05-31
IL257392A (en) 2018-04-30

Similar Documents

Publication Publication Date Title
AR105991A1 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
CO2017006826A2 (es) Compuestos de picolinamida con actividad fungicida con actividad fungicida
UY36481A (es) Compuestos de picolinamida con actividad fúngicida
UY36497A (es) Uso de compuestos de picolinamida con actividad fungicida
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
EA201692219A1 (ru) Способы получения противовирусных соединений
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
UY35639A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201600015A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
AR093036A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR097866A1 (es) Derivados de 4-azaindol
MX2016014197A (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR092170A1 (es) Proceso para la fabricacion de benzoxazinonas
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
TR201809417T4 (tr) Cb2 reseptör agonistleri olarak purin türevleri.
AR096153A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
AR107549A1 (es) Un proceso para preparar compuesto de pirrolo[3,2-d]pirimidina y su intermediario
AR097665A1 (es) Trifluorometilpirimidinonas disustituidas y su uso
AR101798A1 (es) Quinolinas herbicidas
AR098037A1 (es) Derivados de piperazina y su uso como medicamento
MX381489B (es) Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.

Legal Events

Date Code Title Description
FB Suspension of granting procedure